#VisualAbstract: Nivolumab plus ipilimumab may be less effective in females with melanoma compared to males

byTeddy Guo

December 21, 2021

in StudyGraphics

Reading Time: 1 min read

Nivolumab did not improve overall survival in patients with advanced hepatocellular carcinoma

RelatedReports

StudyGraphics

#VisualAbstract: Cutaneous immune-related adverse events were associated with increased survival in patients treated with immune checkpoint inhibitors

January 21, 2022

Chronic Disease

Relatlimab and nivolumab provide greater survival benefit for advanced melanoma

January 17, 2022

#VisualAbstract: Acral lentiginous melanoma may be associated with higher rates of sentinel lymph node positivity compared to other melanoma subtypes

StudyGraphics

#VisualAbstract: Immune checkpoint inhibitors are equally effective for younger and older patients with relapsed or metastatic head and neck squamous cell carcinomas

January 12, 2022

StudyGraphics

#VisualAbstract: Acral lentiginous melanoma may be associated with higher rates of sentinel lymph node positivity compared to other melanoma subtypes

January 11, 2022

Nivolumab may be effective in platinum-resistant ovarian cancer

Nedaplatin-based concurrent chemoradiotherapy is noninferior to cisplatin-based therapy in patients with locoregional nasopharyngeal carcinoma

Drug-coated balloons are noninferior to drug-eluting stents for treatment of small vessel coronary artery disease

Quantitative flow ratio-guided coronary intervention reduces the rate of major cardiac events compared to visual angiography

Many new pediatric asthma cases attributable to obesity

Once-a-week cagrilintide is effective for weight management in overweight and obese patients

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

#VisualAbstract: Nivolumab plus ipilimumab may be less effective in females with melanoma compared to males

#VisualAbstract: Cutaneous immune-related adverse events were associated with increased survival in patients treated with immune checkpoint inhibitors

Relatlimab and nivolumab provide greater survival benefit for advanced melanoma

#VisualAbstract: Immune checkpoint inhibitors are equally effective for younger and older patients with relapsed or metastatic head and neck squamous cell carcinomas

Nivolumab did not improve overall survival in patients with advanced hepatocellular carcinoma

Nedaplatin-based concurrent chemoradiotherapy is noninferior to cisplatin-based therapy in patients with locoregional nasopharyngeal carcinoma

RelatedReports

#VisualAbstract: Cutaneous immune-related adverse events were associated with increased survival in patients treated with immune checkpoint inhibitors

Relatlimab and nivolumab provide greater survival benefit for advanced melanoma

#VisualAbstract: Immune checkpoint inhibitors are equally effective for younger and older patients with relapsed or metastatic head and neck squamous cell carcinomas

#VisualAbstract: Acral lentiginous melanoma may be associated with higher rates of sentinel lymph node positivity compared to other melanoma subtypes

Nedaplatin-based concurrent chemoradiotherapy is noninferior to cisplatin-based therapy in patients with locoregional nasopharyngeal carcinoma

Quantitative flow ratio-guided coronary intervention reduces the rate of major cardiac events compared to visual angiography

Once-a-week cagrilintide is effective for weight management in overweight and obese patients

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

Get Full Access

Recent Reports

Welcome Back!

Create New Account!

Retrieve your password

#VisualAbstract: Nivolumab plus ipilimumab may be less effective in females with melanoma compared to males

RELATED REPORTS

Nivolumab did not improve overall survival in patients with advanced hepatocellular carcinoma

Nedaplatin-based concurrent chemoradiotherapy is noninferior to cisplatin-based therapy in patients with locoregional nasopharyngeal carcinoma

RelatedReports

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

Get Full Access

Recent Reports

Welcome Back!

Create New Account!

Retrieve your password